SciELO - Scientific Electronic Library Online

vol.21 número1Mucormicosis en PediatríaImportancia del laboratorio en el diagnóstico de las micosis invasoras índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


Revista chilena de infectología

versión impresa ISSN 0716-1018


FICA C., ALBERTO. Treatment of systemic fungal infections. First part: Fluconazole, itraconazole and voriconazole. Rev. chil. infectol. [online]. 2004, vol.21, n.1, pp.26-38. ISSN 0716-1018.

Randomized clinical trials in systemic antifungal therapy have traditionally been focused on patients with systemic candidiasis, cryptococcal meningitis, invasive aspergillosis and febrile neutropenic patients with suspicion of a fungal infection. The latter is a known risk factor for infection with filamentous fungi. Itraconazole and voriconazole are active against molds when compared with fluconazole but they are not active against agents of mucormycosis. Both itraconazole and voriconazole cover clinical isolates of Candida albicans and non C. albicans isolates with natural or acquired resistance to fluconazole. Although every triazole compound can be applied on infection caused by C. albicans, only fluconazole has been validated in this setting. Moreover, this compound is the only one approved for the treatment of patients affected by low-risk cryptococcal meningitis. In patients with invasive aspergillosis, only voriconazole has been formally compared and found similar to amphotericin B although open-label studies with intravenous itraconazole also demonstrate its usefulness in this condition. In contrast, in neutropenic febrile patients with suspicion of a fungal infection, intravenous itraconazole but not voriconazole has been shown equivalent to amphotericin B. Triazole compounds differ each other in their dosing schedules, bioavailability, interference of food or changes in gastric pH in absorption, penetration to the CNS, time to reach plasma steady-state concentrations and acquisition costs. Intravenous presentations of itraconazole and voriconazole should not be administered when moderate or mild renal failure is present (< 30 vs < 50 ml/min of creatinine clearence, respectively).

Palabras clave : Invasive mycosis; Systemic antifungal agents; Fluconazole; Itraconazole; Voriconazole.

        · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons